1. Home
  2. RYOJ vs QTTB Comparison

RYOJ vs QTTB Comparison

Compare RYOJ & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RYOJ

rYojbaba Co. Ltd.

N/A

Current Price

$3.26

Market Cap

42.8M

ML Signal

N/A

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$3.60

Market Cap

44.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYOJ
QTTB
Founded
2015
2015
Country
Japan
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.8M
44.3M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
RYOJ
QTTB
Price
$3.26
$3.60
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$7.33
AVG Volume (30 Days)
17.8K
152.2K
Earning Date
02-18-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
115.48
N/A
EPS
0.14
N/A
Revenue
$11,523,472.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.56
N/A
Revenue Growth
12.88
N/A
52 Week Low
$1.81
$1.35
52 Week High
$11.43
$6.37

Technical Indicators

Market Signals
Indicator
RYOJ
QTTB
Relative Strength Index (RSI) N/A 61.11
Support Level N/A $3.22
Resistance Level N/A $3.73
Average True Range (ATR) 0.00 0.27
MACD 0.00 0.01
Stochastic Oscillator 0.00 73.95

Price Performance

Historical Comparison
RYOJ
QTTB

About RYOJ rYojbaba Co. Ltd.

rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: